Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BT8009 |
Synonyms | |
Therapy Description |
BT8009 consists of a Nectin-4 binding bicyclic peptide linked to the toxin MMAE, which delivers the toxin to Nectin-4-expressing tumor cells, potentially resulting in tumor growth inhibition (PMID: 36112771). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BT8009 | BT-8009|BT 8009 | BT8009 consists of a Nectin-4 binding bicyclic peptide linked to the toxin MMAE, which delivers the toxin to Nectin-4-expressing tumor cells, potentially resulting in tumor growth inhibition (PMID: 36112771). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06225596 | Phase II | Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 5 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |